日本語 
CM Plus Co., Ltd. has officially released “pharmo.AI,” an AI search system that supports regulatory intelligence (RI) and pharmaceutical affairs in the pharmaceutical industry. This service comprehensively compiles information issued by domestic and international regulatory authorities into a database and enables fast and accurate searches using RAG (Retrieval-Augmented Generation) technology. By combining access to the latest information provided by AI with the specialized knowledge of our consultants, we aim to ensure the accuracy and reliability of the information required for GxP work and contribute to improving the productivity of pharmaceutical companies.
Development Background The growing problem of “evidence-seeking” in the pharmaceutical industry
While generative AI has made remarkable advances in recent years, challenges remain in practical applications that require strict accuracy, such as the pharmaceutical industry. In particular, regulatory compliance and pharmaceutical affairs require a process of “document search and confirmation,” in which staff manually verify the primary information that supports the information presented by AI. This is due to the inherent characteristics of general-purpose large-scale language models (LLMs), such as “not evaluating the freshness or reliability of information and presenting uncertain information equally,” “lacking accuracy in details such as article numbers,” and “inability to accurately present evidence,” which present obstacles to improving work efficiency.
Overview An integrated platform that connects the latest information, AI, and experts
“pharmo.AI” is an AI search system specialized for the pharmaceutical industry, developed to eliminate the hassle of “searching for and verifying evidence.” By collecting and database-izing information daily from domestic and international regulatory information websites and applying RAG search, it provides a system that allows answers generated from reliable sources to be simultaneously checked along with the underlying information. This allows personnel in charge of RI and pharmaceutical application work to quickly access reliable, up-to-date information. In addition, a “simple consulting service” is available to review AI answers and provide advice, supporting final decision-making.
Also Read: Nxera Pharma to Get $10M from AbbVie for Neuro Project
“pharmo.AI” is more than just a search system. In the future, we aim to use this service as a platform to develop and provide multiple “AI agents” specialized for various tasks in the pharmaceutical industry. Furthermore, we will formalize the knowledge and experience accumulated by our consultants and incorporate it into the AI agents.
SOURCE: PRTimes
English